Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Feb;71(2):282–289. doi: 10.1038/bjc.1995.57

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.

S Kondo 1, D Yin 1, T Morimura 1, H Kubo 1, S Nakatsu 1, J Takeuchi 1
PMCID: PMC2033593  PMID: 7841041

Abstract

We attempted to determine whether calcium channel blockers (CCBs) enhance the anti-tumour activity of cis-diamminedichloroplatinum (cisplatin) against both cisplatin-sensitive human glioblastoma U87 MG cells and cisplatin-resistant U87-MG-CR cells, the latter of which we developed for resistance to cisplatin. Nifedipine, a dihydropyridine class CCB, significantly enhanced the anti-tumour effect of cisplatin on these two cell types in vitro and in vivo. Our findings also indicated that, in the absence of normal extracellular Ca2+ nifedipine was capable of enhancing the cytotoxicity of cisplatin. In addition, this anti-tumour activity was partially inhibited by actinomycin D and cycloheximide, suggesting that it is possibly dependent upon new RNA and protein synthesis. Interestingly, ultrastructural analysis, DNA fragmentation assay and cell cycle analysis demonstrated that synergism between cisplatin and nifedipine results in apoptosis (programmed cell death) at a relatively low concentration of cisplatin, which when tested alone did not induce apoptosis. Furthermore, we demonstrated that nuclei from these cells lack a Ca(2+)-dependent endonuclease that degrade chromatin in the linker region between nucleosomes. In conclusion, our studies suggest that the non-cytotoxic agent nifedipine is able to synergistically enhance the anti-tumour effects of cisplatin on U87-MG and U87-MG-CR cells lacking a Ca(2+)-dependent endonuclease and subsequently to induce apoptosis via interaction of nifedipine with an as yet uncharacterised functional site other than a calcium channel on target cells.

Full text

PDF
282

Images in this article

286Figure 6
on p.286
287Figure 7
on p.287
288Figure 9
on p.288

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990 Feb;2(2):35–43. [PubMed] [Google Scholar]
  2. Arends M. J., Morris R. G., Wyllie A. H. Apoptosis. The role of the endonuclease. Am J Pathol. 1990 Mar;136(3):593–608. [PMC free article] [PubMed] [Google Scholar]
  3. Bakka A., Endresen L., Johnsen A. B., Edminson P. D., Rugstad H. E. Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol Appl Pharmacol. 1981 Nov;61(2):215–226. doi: 10.1016/0041-008x(81)90411-7. [DOI] [PubMed] [Google Scholar]
  4. Barry M. A., Behnke C. A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990 Nov 15;40(10):2353–2362. doi: 10.1016/0006-2952(90)90733-2. [DOI] [PubMed] [Google Scholar]
  5. Bertolone S. J., Baum E. S., Krivit W., Hammond G. D. A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Childrens Cancer Study Group. J Neurooncol. 1989 May;7(1):5–11. doi: 10.1007/BF00149372. [DOI] [PubMed] [Google Scholar]
  6. Cohen J. J., Duke R. C. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol. 1984 Jan;132(1):38–42. [PubMed] [Google Scholar]
  7. Collins R. J., Harmon B. V., Souvlis T., Pope J. H., Kerr J. F. Effects of cycloheximide on B-chronic lymphocytic leukaemic and normal lymphocytes in vitro: induction of apoptosis. Br J Cancer. 1991 Sep;64(3):518–522. doi: 10.1038/bjc.1991.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Del Bino G., Bruno S., Yi P. N., Darzynkiewicz Z. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif. 1992 Nov;25(6):537–548. doi: 10.1111/j.1365-2184.1992.tb01458.x. [DOI] [PubMed] [Google Scholar]
  9. Duke R. C., Chervenak R., Cohen J. J. Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. Proc Natl Acad Sci U S A. 1983 Oct;80(20):6361–6365. doi: 10.1073/pnas.80.20.6361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 1990 Aug-Sep;2(8-9):275–280. [PubMed] [Google Scholar]
  11. Epstein P. M., Fiss K., Hachisu R., Andrenyak D. M. Interaction of calcium antagonists with cyclic AMP phosphodiesterases and calmodulin. Biochem Biophys Res Commun. 1982 Apr 14;105(3):1142–1149. doi: 10.1016/0006-291x(82)91089-0. [DOI] [PubMed] [Google Scholar]
  12. Evans D. L., Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res. 1993 May 1;53(9):2133–2139. [PubMed] [Google Scholar]
  13. Gately D. P., Howell S. B. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer. 1993 Jun;67(6):1171–1176. doi: 10.1038/bjc.1993.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Helson L. Calcium channel blocker enhancement of anticancer drug cytotoxicity--a review. Cancer Drug Deliv. 1984 Fall;1(4):353–361. doi: 10.1089/cdd.1984.1.353. [DOI] [PubMed] [Google Scholar]
  15. Ikeda H., Nakano G., Nagashima K., Sakamoto K., Harasawa N., Kitamura T., Nakamura T., Nagamachi Y. Verapamil enhancement of antitumor effect of cis-diamminedichloroplatinum(II) in nude mouse-grown human neuroblastoma. Cancer Res. 1987 Jan 1;47(1):231–234. [PubMed] [Google Scholar]
  16. Janis R. A., Triggle D. J. New developments in Ca2+ channel antagonists. J Med Chem. 1983 Jun;26(6):775–785. doi: 10.1021/jm00360a001. [DOI] [PubMed] [Google Scholar]
  17. Johnson B. D., Byerly L. Photo-released intracellular Ca2+ rapidly blocks Ba2+ current in Lymnaea neurons. J Physiol. 1993 Mar;462:321–347. doi: 10.1113/jphysiol.1993.sp019558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Jones D. P., McConkey D. J., Nicotera P., Orrenius S. Calcium-activated DNA fragmentation in rat liver nuclei. J Biol Chem. 1989 Apr 15;264(11):6398–6403. [PubMed] [Google Scholar]
  19. Kawai K., Kamatani N., Georges E., Ling V. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J Biol Chem. 1990 Aug 5;265(22):13137–13142. [PubMed] [Google Scholar]
  20. Kelley S. L., Rozencweig M. Resistance to platinum compounds: mechanisms and beyond. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1135–1140. doi: 10.1016/0277-5379(89)90405-7. [DOI] [PubMed] [Google Scholar]
  21. Kessel D., Wilberding C. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Res. 1985 Apr;45(4):1687–1691. [PubMed] [Google Scholar]
  22. Kondo S., Yin D., Morimura T., Oda Y., Kikuchi H., Takeuchi J. Transfection with a bcl-2 expression vector protects transplanted bone marrow from chemotherapy-induced myelosuppression. Cancer Res. 1994 Jun 1;54(11):2928–2933. [PubMed] [Google Scholar]
  23. McConkey D. J., Hartzell P., Amador-Pérez J. F., Orrenius S., Jondal M. Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor complex. J Immunol. 1989 Sep 15;143(6):1801–1806. [PubMed] [Google Scholar]
  24. McConkey D. J., Nicotera P., Hartzell P., Bellomo G., Wyllie A. H., Orrenius S. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. Arch Biochem Biophys. 1989 Feb 15;269(1):365–370. doi: 10.1016/0003-9861(89)90119-7. [DOI] [PubMed] [Google Scholar]
  25. Miyashita T., Reed J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993 Jan 1;81(1):151–157. [PubMed] [Google Scholar]
  26. Motulsky H. J., Snavely M. D., Hughes R. J., Insel P. A. Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors. Circ Res. 1983 Feb;52(2):226–231. doi: 10.1161/01.res.52.2.226. [DOI] [PubMed] [Google Scholar]
  27. Oberhammer F., Wilson J. W., Dive C., Morris I. D., Hickman J. A., Wakeling A. E., Walker P. R., Sikorska M. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J. 1993 Sep;12(9):3679–3684. doi: 10.1002/j.1460-2075.1993.tb06042.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Onoda J. M., Jacobs J. R., Taylor J. D., Sloane B. F., Honn K. V. Cisplatin and nifedipine: synergistic cytotoxicity against murine solid tumors and their metastases. Cancer Lett. 1986 Feb;30(2):181–188. doi: 10.1016/0304-3835(86)90087-x. [DOI] [PubMed] [Google Scholar]
  29. Onoda J. M., Nelson K. K., Taylor J. D., Honn K. V. Cisplatin and nifedipine: synergistic antitumor effects against an inherently cisplatin-resistant tumor. Cancer Lett. 1988 May;40(1):39–47. doi: 10.1016/0304-3835(88)90260-1. [DOI] [PubMed] [Google Scholar]
  30. Onoda J. M., Nelson K. K., Taylor J. D., Honn K. V. In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II). Cancer Res. 1989 Jun 1;49(11):2844–2850. [PubMed] [Google Scholar]
  31. Onoda J. M., Sloane B. F., Honn K. V. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors. Thromb Res. 1984 Jun 1;34(5):367–378. doi: 10.1016/0049-3848(84)90241-x. [DOI] [PubMed] [Google Scholar]
  32. Ormerod M. G., Orr R. M., Peacock J. H. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br J Cancer. 1994 Jan;69(1):93–100. doi: 10.1038/bjc.1994.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ozols R. F., Cunnion R. E., Klecker R. W., Jr, Hamilton T. C., Ostchega Y., Parrillo J. E., Young R. C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987 Apr;5(4):641–647. doi: 10.1200/JCO.1987.5.4.641. [DOI] [PubMed] [Google Scholar]
  34. Perez R. P., Hamilton T. C., Ozols R. F. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther. 1990;48(1):19–27. doi: 10.1016/0163-7258(90)90015-t. [DOI] [PubMed] [Google Scholar]
  35. Randolph V. L., Vallejo A., Spiro R. H., Shah J., Strong E. W., Huvos A. G., Wittes R. E. Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy. Cancer. 1978 Feb;41(2):460–467. doi: 10.1002/1097-0142(197802)41:2<460::aid-cncr2820410213>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  36. Rodriguez-Tarduchy G., Collins M., López-Rivas A. Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin-3 and calcium ionophores. EMBO J. 1990 Sep;9(9):2997–3002. doi: 10.1002/j.1460-2075.1990.tb07492.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Rodriguez-Tarduchy G., Malde P., Lopez-Rivas A., Collins M. K. Inhibition of apoptosis by calcium ionophores in IL-3-dependent bone marrow cells is dependent upon production of IL-4+. J Immunol. 1992 Mar 1;148(5):1416–1422. [PubMed] [Google Scholar]
  38. Schmid F. A., Otter G. M., Stock C. C. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard. Cancer Res. 1980 Mar;40(3):830–833. [PubMed] [Google Scholar]
  39. Sexauer C. L., Khan A., Burger P. C., Krischer J. P., van Eys J., Vats T., Ragab A. H. Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study. Cancer. 1985 Oct 1;56(7):1497–1501. doi: 10.1002/1097-0142(19851001)56:7<1497::aid-cncr2820560703>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  40. Sorenson C. M., Barry M. A., Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst. 1990 May 2;82(9):749–755. doi: 10.1093/jnci/82.9.749. [DOI] [PubMed] [Google Scholar]
  41. Telford W. G., King L. E., Fraker P. J. Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif. 1991 Sep;24(5):447–459. doi: 10.1111/j.1365-2184.1991.tb01173.x. [DOI] [PubMed] [Google Scholar]
  42. Timmer-Bosscha H., Hospers G. A., Meijer C., Mulder N. H., Muskiet F. A., Martini I. A., Uges D. R., de Vries E. G. Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst. 1989 Jul 19;81(14):1069–1075. doi: 10.1093/jnci/81.14.1069. [DOI] [PubMed] [Google Scholar]
  43. Tsuruo T., Iida H., Nojiri M., Tsukagoshi S., Sakurai Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983 Jun;43(6):2905–2910. [PubMed] [Google Scholar]
  44. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 1982 Nov;42(11):4730–4733. [PubMed] [Google Scholar]
  45. Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep. 1983 Oct;67(10):889–894. [PubMed] [Google Scholar]
  46. Walker P. R., Smith C., Youdale T., Leblanc J., Whitfield J. F., Sikorska M. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res. 1991 Feb 15;51(4):1078–1085. [PubMed] [Google Scholar]
  47. Wyllie A. H., Kerr J. F., Currie A. R. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;68:251–306. doi: 10.1016/s0074-7696(08)62312-8. [DOI] [PubMed] [Google Scholar]
  48. Yin D., Kondo S., Takeuchi J., Morimura T. Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett. 1994 Feb 14;339(1-2):73–75. doi: 10.1016/0014-5793(94)80387-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES